Recent blog posts
Zeripatamig Biologics Sequence Review Report 2026: CD47 × CD19 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Zeripatamig Biologics Sequence Review Report 2026: CD47 × CD19 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zeripatamig, an antibody targeting CD47 × CD19.
Read →
Ralzapastotug Biologics Sequence Review Report 2026: TIGIT Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Ralzapastotug Biologics Sequence Review Report 2026: TIGIT Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ralzapastotug, an antibody targeting TIGIT.
Read →
Prafnosbart Biologics Sequence Review Report 2026: ACVR1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Prafnosbart Biologics Sequence Review Report 2026: ACVR1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Prafnosbart, an antibody targeting ACVR1.
Read →
Pradusinstobart Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Pradusinstobart Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pradusinstobart, an antibody targeting PD-1.
Read →
Patecibart Biologics Sequence Review Report 2026: EDNRA Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Patecibart Biologics Sequence Review Report 2026: EDNRA Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Patecibart, an antibody targeting EDNRA.
Read →
Ozekibart Biologics Sequence Review Report 2026: TNFRSF10B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Ozekibart Biologics Sequence Review Report 2026: TNFRSF10B Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ozekibart, an antibody targeting TNFRSF10B.
Read →
Obertamig Biologics Sequence Review Report 2026: CD3E × HLA-G Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Obertamig Biologics Sequence Review Report 2026: CD3E × HLA-G Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Obertamig, an antibody targeting CD3E × HLA-G.
Read →
Lipustobart Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Lipustobart Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lipustobart, an antibody targeting PD-1.
Read →
Epacmarstobart Biologics Sequence Review Report 2026: SIRPA Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Epacmarstobart Biologics Sequence Review Report 2026: SIRPA Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Epacmarstobart, an antibody targeting SIRPA.
Read →
Ciduvectamig Biologics Sequence Review Report 2026: TMEFF2 × CD3E Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Ciduvectamig Biologics Sequence Review Report 2026: TMEFF2 × CD3E Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ciduvectamig, an antibody targeting TMEFF2 × CD3E.
Read →
Uprevstobart Biologics Sequence Review Report 2026: CD73 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Uprevstobart Biologics Sequence Review Report 2026: CD73 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Uprevstobart, an antibody targeting CD73.
Read →
Solrikitug Biologics Sequence Review Report 2026: TSLP Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
Solrikitug Biologics Sequence Review Report 2026: TSLP Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solrikitug, an antibody targeting TSLP.
Read →